Cancer-specific cytotoxicity of Ringer's acetate solution irradiated by cold atmospheric pressure plasma

Camelia Miron1, Kenji Ishikawa1, Satoshi Kashiwagura1

  • 1Center for Low-temperature Plasma Sciences, Nagoya University, Nagoya, Japan.

Free Radical Research
|April 17, 2023
PubMed

Insights

Plasma-activated organics show potential in cancer therapy by increasing cancer cell death. Specific compounds like acetic anhydride and ethyl acetate influence cell viability, offering new avenues for treatment.

Area of Science:

  • Biomedical Engineering
  • Plasma Physics
  • Cancer Research

Background:

  • Cold atmospheric pressure plasmas are emerging tools for cancer treatment.
  • Understanding the role of plasma-generated reactive species and their biochemical pathway activation is crucial for optimizing cancer therapy.

Purpose of the Study:

  • To explore the concept of antitumoral plasma-activated organics to enhance cancer cell cytotoxicity.
  • To investigate the chemical compounds generated from plasma-treated Ringer's acetate solution and their effects on breast cells.

Main Methods:

  • Ringer's acetate solution was treated with cold atmospheric pressure plasma.
  • Chemical compounds formed in the plasma-treated solution were identified.
  • The effects of these compounds on non-tumorigenic (MCF-10A) and cancerous (MCF-7) breast cells were evaluated by assessing cell viability.

Main Results:

  • Plasma treatment of Ringer's acetate solution generated various chemical compounds.
  • These plasma-derived compounds exhibited both stimulatory and inhibitory effects on cell viability, dependent on concentration.
  • Compounds such as acetic anhydride and ethyl acetate were identified as potentially significant in plasma-based cancer therapy.

Conclusions:

  • Plasma-activated organics present a novel strategy for cancer therapy.
  • The identified compounds, beyond reactive oxygen and nitrogen species (RONS), play a key role in modulating cancer cell viability.
  • Further research into these specific compounds could lead to more effective plasma-based cancer treatments.